Amgen
AMGN
$216.93
Share price
-0.24%
Change (1 day)
-15.51%
Change (1 year)
Categories
The biotechnology company Amgen was founded in 1980 as AMGen. With approximately 20,000 employees, Amgen is one of the world's largest biotechnology companies with annual sales of approximately $ 24 billion in 2018.
Amgen (AMGN) - Total debt
Total debt on the balance sheet as of March 2023 : $61.59 B
According to Amgen's latest financial reports the company's total debt is $61.59 B. A company’s total debt is the sum of all current and non-current debts.
Amgen - Total debt on balance sheet (from 2001 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2022-12-31 | $38.94 B | 16.92% |
| 2021-12-31 | $33.30 B | 0.98% |
| 2020-12-31 | $32.98 B | 10.31% |
| 2019-12-31 | $29.90 B | -11.87% |
| 2018-12-31 | $33.92 B | -4% |
| 2017-12-31 | $35.34 B | 2.16% |
| 2016-12-31 | $34.59 B | 9.63% |
| 2015-12-31 | $31.55 B | 2.74% |
| 2014-12-31 | $30.71 B | -4.4% |
| 2013-12-31 | $32.12 B | 21.11% |
| 2012-12-31 | $26.52 B | 23.81% |
| 2011-12-31 | $21.42 B | 60.37% |
| 2010-12-31 | $13.36 B | 26.04% |
| 2009-12-31 | $10.60 B | 4.18% |
| 2008-12-31 | $10.17 B | -8.96% |
| 2007-12-31 | $11.17 B | 24.02% |
| 2006-12-31 | $9.01 B | 127.75% |
| 2005-12-31 | $3.95 B | -22.56% |
| 2004-12-31 | $5.11 B | 65.94% |
| 2003-12-31 | $3.07 B | -2.87% |
| 2002-12-31 | $3.17 B | 881.91% |
| 2001-12-31 | $0.32 B |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $39.65 B | -35.61% | 🇺🇸 USA |
 Pfizer PFE | $34.87 B | -43.39% | 🇺🇸 USA |
 AbbVie ABBV | $63.27 B | 2.72% | 🇺🇸 USA |
 Eli Lilly LLY | $18.88 B | -69.34% | 🇺🇸 USA |
 Biogen BIIB | $6.60 B | -89.27% | 🇺🇸 USA |
 Gilead Sciences GILD | $25.23 B | -59.02% | 🇺🇸 USA |
 Illumina ILMN | $2.98 B | -95.16% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $39.37 B | -36.08% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $25.89 B | -57.96% | 🇬🇧 UK |